View Article

Abstract

Bosom malignant growth treatment is multidisciplinary. Most of ladies with beginning phase bosom disease are possibility for bosom saving a medical procedure with radiotherapy or mastectomy. The gamble of neighborhood repeat and the opportunity of endurance doesn't vary with these methodologies. Sentinel hub biopsy is utilized for axillary arranging, and individualized approaches are limiting the requirement for axillary analyzation in sentinel hub positive ladies. Adjuvant fundamental treatment is utilized in most of ladies in light of demonstrated endurance benefit, and sub-atomic profiling to individualize therapy in view of hazard is currently a clinical reality for patients with chemical receptor-positive malignant growths. Follow-up reconnaissance comprises of a set of experiences, actual assessment, and yearly mammography. Following adjuvant fundamental treatment, there is presently no proof that standard imaging further develops results without any side effects.

Keywords

Breast cancer treatment, local therapy, adjuvant therapy, breast-conserving therapy, mastectomy, neoadjuvant chemotherapy, breast cancer surveillance, bosom Treatment.

Reference

  1. Www.wikipdia.com
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2018;68(6):394-424. doi:10.3322/ caac.21492
  3. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/ breast.html. Accessed January 23, 2018.
  4. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034
  5. Morrow M. Physical examination of the breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia, PA: Wolters
  6. Kluwer Health; 2014:chap3. [3:02 pm, 09/11/2023] m: Weigelt, B.; Horlings, H.M.; Kreike, B.; Hayes, M.M.; Hauptmann, M.; Wessels, L.F.A.; De Jong, D.; van de Vijver, M.; Veer, L.J.V.;
  7. Peterse, J.L. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008, 216, 141–150.
  8. Erber, R.; Hartmann, A. Histology of Luminal Breast Cancer. Breast Care 2020, 15, 327–336
  9. Howlader, N.; Altekruse, S.F.; Li, C.I.; Chen, V.W.; Clarke, C.A.; Ries, L.A.G.; Cronin, K.A. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J. Natl. Cancer Inst. 2014, 106, djuOncolVIi
  10. Weigelt, B.; Geyer, F.C.; Reis-Filho, J.S. Histological types of breast cancer: How special are they? Mol. Oncol. 2010, 4, 192–208.
  11. Makki, J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin. Med. Insights Pathol. 2015, 8, 23–31.[CrossRef]
  12. Raj-Kumar, P.-K.; Liu, J.; Hooke, J.A.; Kovatich, A.J.; Kvecher, L.; Shriver, C.D.; Hu, H. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci. Rep. 2019, 9, 7956.
  13. Ranjit, K. Breast cancer. Lancet 2005, 365, 1742.
  14. Roberts, S.A.; Lawrence, M.S.; Klimczak, L.J.; Grimm, S.A.; Fargo, D.; Stojanov, P.; Kiezun, A.; Kryukov, G.; Carter, S.L.; Saksena, G.; et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45, 970–976.
  15. .Plasilova, M.L.; Hayse, B.; Killelea, B.K.; Horowitz, N.R.; Chagpar, A.B.; Lannin, D.R. Features of triple-negative breast cancer.
  16. Newman, L.A.; Reis-Filho, J.S.; Morrow, M.; Carey, L.A.; King, T.A. The 2014 Society of Surgical Oncology Susan G. Komen for
  17. the Cure Symposium: Triple-Negative Breast Cancer. Ann. Surg. Oncol. 2014, 22, 874–882. 2016, 95,subtyping.Pareja, F. Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2016, 2, 16036.
  18. Wetterskog, D. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast
  19. Badve, S.; Dabbs, D.J.; Schnitt, S.J.; Baehner, F.L.; Decker, T.; Eusebi, V.; Fox, S.; Ichihara, S.; Jacquemier, J.;
  20. Lakhani, S.R.; et al. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2010, 24, 157–167.. J. Pathol. 2012, 226, 84–96
  21. Prat, A.; Parker, J.S.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, J.I.; He, X.; Perou, C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12, R68.
  22. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.;
  23. Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-MesenchymRes2
  24. Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–41Whel.Dias, K.; Dvorkin-Gheva, A.; Hallett, R.M.; Wu, Y.; Hassell, J.; Pond, G.R.; Levine, M.; Whelan, T.; Bane, A.L. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE 2017, 12, e0168669.
  25. Morel, A.-P.; Ginestier, C.; Pommier, R.M.; Cabaud, O.; Ruiz, E.; Wicinski, J.; Devouassoux-Shisheboran, M.; Combaret, V.; Finetti, P.; Chassot, C.; et al. A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nat. Med. 2017, 23, 568–578
  26. Acton, A. (2013). Breast Cancer New Insights for the Healthcare Professional. Atlanta, Georgia: Scholarly Editions.
  27. .González-Jiménez, E., García, P., Aguilar, M., Padilla, C., & Álvarez, J. (2013). Breastfeeding and the Prevention of Breast Cancer: a Retrospective Review of Clinical Histories. Journal of Clinical Nursing, 23(1), 2397-2403.
  28. 3.Kotsopoulos, J., Lubinski, J., Salmena, L., Lynch, H., Kim-Sing, C., Foulkes, W., Ghadirian, P., Neuhausen, S., Demsky, R., Tung, N., Ainsworth, P., Senter, L., Eisen, A., Eng, C., Singer, C., Ginsburg, O., Blum, J., Huzarski, T., Poll, A., Sun, P. and Narod, S. (2012). Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 14(2), p.R42
  29. .Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–4124.
  30. Youtube.com ganeshay medical educganesha72
  31. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–4124.
  32. Folkerd, E.; Dowsett, M. Sex hormones and breast cancer risk and prognosis. Breast 2013, 22, S38–S43.
  33. Stat Bite: Lifetime Probability among Females of Dying of Cancer. JNCI J. Natl. Cancer Inst. 2004, 96, 1311–1321.9
  34. Seal, S.; The Breast Cancer Susceptibility Collaboration (UK); Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; Chagtai, T.; Jayatilake, H.; Ahmed, M.; et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006, 38, 1239–1242
  35. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early- detection/mammograms.html
  36. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-ultrasound.html
  37. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html
  38. www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/mri-for-cancer.html
  39. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. Curr. Med. Chem. 2011, 18, 513–522. [CrossReBass3
  40. Jones, K.L.; Buzdar, A.U. A review of adjuvant hormonal therapy in breast cancer. Endocr.-Related Cancer 2004, 11, 391–406 [CrossRef]
  41. Rouzier, R.; Perou, C.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin. Cancer Res. 2005, 11, 5678–5685.[CrossRef]
  42. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. Curr. Med. Chem. 2011, 18, 513–522. [CrossRef]
  43. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/ breast.html. Accessed January 23, 2018.4XL
  44. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034
  45. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034

Photo
M.B.GUNJAL
Corresponding author

Nandkumar Shinde College of Pharmacy, Vaijapur

Photo
M. G. Shaikh
Co-author

Nandkumar Shinde College of Pharmacy, Vaijapur

Photo
M.S. Adhikar
Co-author

Nandkumar Shinde College of Pharmacy, Vaijapur

Photo
S. R. Agrawal
Co-author

Nandkumar Shinde College of Pharmacy, Vaijapur

M. B. Gunjal*, M. G. Shaikh, M.S. Adhikar, S. R. Agrawal, Review on : Breast cancer their Diagnosis Treatment and Therapies used, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 12, 307- 316. https://doi.org/10.5281/zenodo.10369595

More related articles
Polyherbal Churn For Treatment Of Diabetes...
Tushar Sanjay Bochare, Nishan Bobade , Vedant Sanjay Ganorkar , V...
Synthesis, Characterization And Anti-Bacterial Act...
R.Parasuraman , Vardhineedi Shirisha, K Pavan kumar, N Namitha, M...
Development And Validation of New RP HPLC Method F...
P. Seetharamaiah, Nagaraju Pappula, JVLN. Seshagiri Rao, D. Gowri...
A Review On Epilepsy Its Treatment...
Misal Vaishnavi , Deokar Shivprasad S, Thombre Vaishnavi B, Bansod Vaishnavi A, Bhande Vaishnavi B, ...
Formulation And Evaluation of Multipurpose Herbal Cream...
Akash Jayaprakash, Ahalya. S. S, Arya Babu, V. F. Sony, Vishnu Narayanan, Dr. Prasobh. G. R, Varsha....
Related Articles
Pharmaceutical Formulation and Development: A Comprehensive Review...
Tushar B. Aher, Prof. Poonam P. Khade, Dr. Megha T. Salve, ...
Hand And Foot Syndrome With Hyperpigmentation By Capecitabine...
Asra Jabeen, Masrat Nabi, Sheikh H. Ismail, Zahid Akhtar, Sami Magray, Nasreen Chashoo, ...
Phytochemical Screening Photoluminance Study and TLC (Thin Layer Chromatography)...
Vishakha Patial, Kanika, Dev Prakash Dahiya, Chinu Kumari, Rahul Sharma, Richa Kumari, Nikhil Rana, ...
Polyherbal Churn For Treatment Of Diabetes...
Tushar Sanjay Bochare, Nishan Bobade , Vedant Sanjay Ganorkar , Vaishnavi Chavhan, Ashweeni Kedar, ...
More related articles
Polyherbal Churn For Treatment Of Diabetes...
Tushar Sanjay Bochare, Nishan Bobade , Vedant Sanjay Ganorkar , Vaishnavi Chavhan, Ashweeni Kedar, ...
Synthesis, Characterization And Anti-Bacterial Activity Of Novel Chalcone Deriva...
R.Parasuraman , Vardhineedi Shirisha, K Pavan kumar, N Namitha, M Keerthana , N Prashanth reddy, ...
Development And Validation of New RP HPLC Method For the Simultaneous Estimation...
P. Seetharamaiah, Nagaraju Pappula, JVLN. Seshagiri Rao, D. Gowrisankar, ...
Polyherbal Churn For Treatment Of Diabetes...
Tushar Sanjay Bochare, Nishan Bobade , Vedant Sanjay Ganorkar , Vaishnavi Chavhan, Ashweeni Kedar, ...
Synthesis, Characterization And Anti-Bacterial Activity Of Novel Chalcone Deriva...
R.Parasuraman , Vardhineedi Shirisha, K Pavan kumar, N Namitha, M Keerthana , N Prashanth reddy, ...
Development And Validation of New RP HPLC Method For the Simultaneous Estimation...
P. Seetharamaiah, Nagaraju Pappula, JVLN. Seshagiri Rao, D. Gowrisankar, ...